An interventional study of EMDR and SSRIs in PTSD - Post Traumatic Stress Disorder, sponsored by Asad Ullah Jan. Completed at 2 sites in Pakistan. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2026-05-07.
Sponsored by Asad Ullah Jan · Not applicable, Interventional, and Treatment
This randomized controlled trial investigates the comparative effectiveness of Eye Movement Desensitization and Reprocessing (EMDR) therapy and selective serotonin reuptake inhibitors (SSRIs) in fostering post-traumatic growth among patients diagnosed with post-traumatic stress disorder (PTSD). Participants will be randomized to receive either EMDR therapy or standard SSRI pharmacotherapy. The primary objective is to evaluate the extent of psychological growth and recovery achieved through each intervention, aiming to guide future therapeutic strategies for PTSD.
135 studies on the registry are indexed under Combat Disorders; 70 are open to participants now.
This study's enrollment of 130 is above the median of 76 across 113 interventional studies indexed under Combat Disorders.
Browse Combat Disorders studies →Asad Ullah Jan is the lead sponsor of 4 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Clinical diagnosis of Post-Traumatic Stress Disorder (PTSD) based on DSM-5 criteria
Willingness to participate and provide informed consent
Ability to comply with study procedures
Exclusion Criteria:
Current diagnosis of psychotic disorder, bipolar disorder, or severe major depressive episode with psychotic features
Active substance use disorder within the past 6 months
Severe cognitive impairment or inability to complete study assessments
EMDR therapy
Behavioral: EMDR
Acting as control group
Drug: SSRIs
Participants will receive structured EMDR therapy sessions conducted by trained therapists following standard EMDR protocols. Sessions will occur weekly over a 6 week period.
Participants will receive pharmacotherapy with an SSRI prescribed according to standard clinical guidelines for PTSD, monitored by a psychiatrist over a 6-week period.
Post-Traumatic Growth (PTG) measured by Post-Traumatic Growth Inventory (PTGI)
Change in PTGI total score from baseline to 6 weeks.
Time frame: 6 weeks
PTSD symptom severity measured by PTSD Checklist
Change in PTSD Checklist total score from baseline to 6 weeks.
Time frame: 6 weeks
Plan to share: No — Privacy concerns and confidentiality protections for participants limit the feasibility of public data sharing.
No publications or documents are linked to this record.
This study is completed, as verified in May 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Asad Ullah Jan